Estimates of cancer incidence and mortality in Europe in 2008, Eur J Cancer. mars, vol.46, issue.4, pp.765-81, 2010. ,
, Le cancer du sein -Les cancers les plus fréquents
,
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy, BMC Med. 18 déc, vol.13, issue.1, p.303, 2015. ,
Breast cancer intrinsic subtype classification, clinical use and future trends, Am J Cancer Res, vol.5, issue.10, pp.2929-2972, 2015. ,
Prise en charge du cancer du sein, J Radiol Diagn Interv. juill, vol.95, issue.7-8, pp.740-744, 2014. ,
The PAM50 Riskof-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer, Clin Cancer Res. 1 mars, vol.20, issue.5, pp.1298-305, 2014. ,
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay, BMC Med Genomics. déc, vol.8, issue.1, p.54, 2015. ,
, Poursuivre la recherche clinique pour positionner utilement les signatures génomiques dans la prise en charge des cancers du sein
, Disponible sur
Hormone receptor positive breast cancer: state of the art, Curr Opin Obstet Gynecol. déc, vol.1, 2017. ,
Effectiveness of Added Targeted Therapies to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-analysis, Clin Breast Cancer. juin, p.1526820919303234, 2019. ,
, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of longterm outcome among 100 000 women in 123 randomised trials, The Lancet. févr, vol.379, issue.9814, pp.432-476, 2012.
Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery, Crit Rev Oncol Hematol. févr, vol.134, pp.10-21, 2019. ,
, Haute Autorité de santé définissant les actes et prestations pour l'ALD n° 30 « Tumeur maligne
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers, Clin Cancer Res. 1 avr, vol.10, issue.7, pp.2473-81, 2004. ,
Ovarian cancer in Lynch syndrome; a systematic review, Eur J Cancer. mars, vol.55, pp.65-73, 2016. ,
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status, J Ovarian Res. déc, vol.12, issue.1, p.9, 2019. ,
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, J Clin Oncol. 10 juin, vol.30, issue.17, pp.2039-2084, 2012. ,
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer, Gynecol Oncol, vol.139, issue.1, pp.10-16, 2015. ,
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol. juill, vol.15, issue.8, pp.852-61, 2014. ,
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebocontrolled, double-blind, phase 2 trial, Lancet Oncol, vol.17, issue.11, pp.1579-89, 2016. ,
Genetic Testing by Cancer Site: Ovary, Cancer J, vol.18, issue.4, pp.320-327, 2012. ,
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, vol.266, issue.5182, pp.66-71, 1994. ,
Identification of the breast cancer susceptibility gene BRCA2, Nature. déc, vol.378, issue.6559, pp.789-92, 1995. ,
, Oncogénétique en 2016 -Consultations, laboratoires et suivi -Ref : ADONCOG17 [Internet
Mutation and Cancer: Statistical Study of Retinoblastoma, Proc Natl Acad Sci. 1 avr, vol.68, issue.4, pp.820-823, 1971. ,
Principles of Cancer Genetics, Bunz F, éditeur, pp.75-134, 2016. ,
Linkage of earlyonset familial breast cancer to chromosome 17q21, Science. 21 déc, vol.250, issue.4988, pp.1684-1693, 1990. ,
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 30 sept, vol.265, pp.2088-90, 1994. ,
Myriad Genetics: In the eye of the policy storm, Genet Med Off J Am Coll Med Genet. avr, vol.12, issue.4, pp.39-70, 2010. ,
, Association for Molecular Pathology et al. against US Patent and Trademark Office, Document, vol.255
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer, J Natl Compr Canc Netw. juin, vol.15, issue.6, pp.797-803, 2017. ,
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2, Genet Med. mai, vol.12, issue.5, pp.245-59, 2010. ,
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, JAMA. 20 juin, vol.317, issue.23, p.2402, 2017. ,
The role of BRCA1 and BRCA2 in prostate cancer, Asian J Androl. mai, vol.14, issue.3, pp.409-423, 2012. ,
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers, Br J Cancer, vol.107, 2005. ,
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts: BRCA1/2 Germline Mutations in Pancreatic Cancer, Cancer. 1 juill, vol.120, issue.13, pp.1960-1967, 2014. ,
Treasure Island (FL): StatPearls Publishing, StatPearls [Internet, 2019. ,
Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. Mol Cell. juin, vol.22, issue.6, pp.719-748, 2006. ,
Breast-Cancer Risk in Families with Mutations in PALB2, N Engl J Med. 7 août, vol.371, issue.6, pp.497-506, 2014. ,
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care, J Clin Oncol. mai, vol.34, issue.13, pp.1455-1464, 2016. ,
Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families, Genet Med Off J Am Coll Med Genet, vol.20, issue.12, pp.1677-86, 2018. ,
CHEK2 and ATM rare variants and cancer risk: data from COGS, J Med Genet. déc, vol.53, issue.12, pp.800-811, 2016. ,
Germline RAD51C mutations confer susceptibility to ovarian cancer, Nat Genet. 26 avr, vol.44, p.475, 2012. ,
Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet. 7 août, vol.43, p.879, 2011. ,
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer, JNCI J Natl Cancer Inst. 5 avr, p.45, 2019. ,
A central role for cadherin signaling in cancer, Exp Cell Res. sept, vol.358, issue.1, pp.78-85, 2017. ,
Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond, JAMA Oncol. 1 avr, vol.1, issue.1, p.23, 2015. ,
Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria, J Natl Cancer Inst, vol.105, issue.21, pp.1607-1623, 2013. ,
Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients, Hered Cancer Clin Pract. 17 juin, vol.8, issue.1, p.6, 2010. ,
High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome, J Med Genet. avr, vol.50, issue.4, pp.255-63, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-02168104
Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome, JAMA. 8 juin, vol.305, issue.22, p.2304, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00780536
,
, Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers, J Clin Oncol. 20 juill, vol.33, issue.21, pp.2345-52, 2015.
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations, Eur J Cancer. sept, vol.101, pp.254-62, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02375757
Higherthan-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history, Hum Mutat. déc, vol.38, issue.12, pp.1723-1753, 2017. ,
Recommandations françaises du Groupe Génétique et Cancer pour l'analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l'ovaire, Bull Cancer, vol.105, issue.10, pp.907-924, 2018. ,
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations, Nucleic Acids Res. 1 mars, vol.26, issue.6, pp.1396-400, 1998. ,
High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families, Fam Cancer. déc, vol.13, issue.4, pp.603-612, 2014. ,
,
, EMMA, a cost-and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients, Hum Mutat. mars, vol.32, issue.3, pp.325-359, 2011.
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol, vol.10, issue.3, p.25, 2009. ,
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing, N Engl J Med. 8 mars, vol.366, issue.10, pp.883-92, 2012. ,
OutLyzer: software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice, Oncotarget, vol.7, issue.48, 2016. ,
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data, Nucleic Acids Res. 1 sept, vol.38, issue.16, pp.164-164, 2010. ,
HGVS Recommendations for the Description of Sequence Variants, Update. Hum Mutat. juin, vol.37, issue.6, pp.564-573, 2016. ,
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med Off J Am Coll Med Genet. mai, vol.17, issue.5, pp.405-429, 2015. ,
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, vol.29, issue.11, pp.1282-91, 2008. ,
dbSNP: the NCBI database of genetic variation, Nucleic Acids Res. 1 janv, vol.29, issue.1, pp.308-319, 2001. ,
Universal mutation database): a generic software to build and analyze locus-specific databases, Hum Mutat, vol.15, issue.1, pp.86-94, 2000. ,
BRCA Share: A Collection of Clinical BRCA Gene Variants: HUMAN MUTATION, Hum Mutat. déc, vol.37, issue.12, pp.1318-1346, 2016. ,
BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. Eng C, éditeur, PLOS Genet. 26 déc, vol.14, issue.12, p.1007752, 2018. ,
A method and server for predicting damaging missense mutations, Nat Methods. avr, vol.7, issue.4, pp.248-257, 2010. ,
Human Splicing Finder: an online bioinformatics tool to predict splicing signals, Nucleic Acids Res. mai, vol.37, issue.9, pp.67-67, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00396239
Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals, J Comput Biol. mars, vol.11, issue.2-3, pp.377-94, 2004. ,
Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort, Nucleic Acids Res. 6 sept, vol.46, issue.15, pp.7913-7936, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01910334
Genome sequencing identifies major causes of severe intellectual disability, Nature. juill, vol.511, issue.7509, pp.344-351, 2014. ,
Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion, Hum Mutat, vol.9, issue.5, pp.452-459, 1997. ,
Somatic Mosaicism: A Common Cause of Classic Disease in Tumor-Prone Syndromes? Lessons from Type 2 Neurofibromatosis, Am J Hum Genet. sept, vol.63, issue.3, pp.727-763, 1998. ,
Mechanisms and consequences of somatic mosaicism in humans, Nat Rev Genet, vol.3, issue.10, pp.748-58, 2002. ,
Review and hypotheses: somatic mosaicism: observations related to clinical genetics, Am J Hum Genet, vol.43, issue.4, pp.355-63, 1988. ,
, Arch Dermatol, vol.24, issue.4, p.712, 1931.
Mosaic Neurofibromatosis Type 1: A Systematic Review, Pediatr Dermatol. janv, vol.33, issue.1, pp.9-17, 2016. ,
, Neurofibromatosis, vol.2
, , 1993.
Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing, Genet Med, 2019. ,
Next generation sequencing in sporadic retinoblastoma patients reveals somatic mosaicism, Eur J Hum Genet, vol.23, issue.11, pp.1523-1553, 2015. ,
Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations, Oncogene. mars, vol.35, issue.10, pp.1324-1331, 2016. ,
De novo mutations in human genetic disease, Nat Rev Genet. août, vol.13, issue.8, pp.565-75, 2012. ,
Impact of BRCA mutations on female fertility and offspring sex ratio, Am J Hum Biol, 2009. ,
BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. Fei P, éditeur, PLOS ONE. 5 juin, vol.10, issue.6, p.127363, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01647108
Low-level constitutional mosaicism of a de novoBRCA1 gene mutation, Br J Cancer. févr, vol.112, issue.4, pp.765-773, 2015. ,
A germline mosaic BRCA1 exon deletion in a woman with bilateral basal-like breast cancer: Letter to the Editor, Clin Genet. sept, vol.84, issue.3, pp.297-306, 2013. ,
Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study: Table 1, Cancer Res. 15 juin, vol.70, issue.12, pp.4795-800, 2010. ,
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status, Br J Cancer. mars, vol.102, issue.7, pp.1091-1099, 2010. ,
High frequency of de novo mutations in Li-Fraumeni syndrome, J Med Genet, vol.46, issue.10, pp.689-93, 2009. ,
Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome, J Med Genet, pp.2017-104976, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02355680
Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome, Am J Med Genet A. févr, vol.149, issue.2, pp.206-217, 2009. ,
A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing. Mazoyer S, éditeur, PLoS ONE. 8 mai, vol.9, issue.5, p.96531, 2014. ,
Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome, Genet Med. sept, vol.14, issue.9, pp.819-841, 2012. ,
When Overgrowth Bumps Into Cancer: The PTEN-Opathies: AMERICAN JOURNAL OF MEDICAL GENETICS PART C (SEMINARS IN MEDICAL GENETICS), Am J Med Genet C Semin Med Genet. mai, vol.163, issue.2, pp.114-135, 2013. ,
A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing, Genet Med. déc, vol.15, issue.12, pp.1004-1011, 2013. ,
Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome, Fam Cancer. sept, vol.13, issue.3, pp.459-67, 2014. ,
PTEN mosaicism with features of Cowden syndrome: PTEN mosaicism with features of CS, Clin Genet. déc, vol.84, issue.6, pp.593-598, 2013. ,
Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity, Eur J Hum Genet. juill, vol.15, issue.7, pp.767-73, 2007. ,
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway, Dermatol Clin. janv, vol.35, issue.1, pp.51-60, 2017. ,
Determining the frequency of de novo germline mutations in DNA mismatch repair genes, J Med Genet. 1 août, vol.48, issue.8, pp.530-534, 2011. ,
Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors, Fam Cancer. mars, vol.12, issue.1, pp.27-33, 2013. ,
Blepharo-cheilo-dontic (BCD) syndrome: Expanding the phenotype, case report and review of literature, Am J Med Genet A. juin, vol.164, issue.6, pp.1525-1534, 2014. ,
Variants in members of the cadherin-catenin complex, CDH1 and CTNND1, cause blepharocheilodontic syndrome, Eur J Hum Genet. févr, vol.26, issue.2, pp.210-219, 2018. ,
A novel de novo CDH1 germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsensemediated mRNA decay. Cold Spring Harb Mol Case Stud, vol.4, 2018. ,
Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc, vol.17, pp.745-754, 2014. ,
De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer, Clin Genet. sept, vol.82, issue.3, pp.283-290, 2012. ,
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. juin, vol.23, issue.6, pp.703-716, 2017. ,
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours, Nat Genet. avr, vol.9, issue.4, pp.439-482, 1995. ,
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer, Cancer Res. 15 août, vol.56, issue.16, pp.3622-3627, 1996. ,
Frequency of germline and somatic BRCA1 mutations in ovarian cancer, Clin Cancer Res Off J Am Assoc Cancer Res. oct, vol.4, issue.10, pp.2433-2440, 1998. ,
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer, J Clin Oncol. août, vol.28, issue.22, pp.3570-3576, 2010. ,
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting, Oncotarget, vol.8, issue.27, 2017. ,
, The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours, Nature, vol.490, issue.7418, pp.61-70, 2012.
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing, Breast Cancer Res Treat. juin, vol.145, issue.3, pp.707-721, 2014. ,
Mutational landscape and significance across 12 major cancer types, Nature, vol.502, issue.7471, pp.333-342, 2013. ,
Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis, Mol Biol Rep. juin, vol.46, issue.3, pp.3325-3357, 2019. ,
CA125-A Test with a Change of Heart. Heart Lung Circ, vol.20, pp.634-674, 2011. ,
, Cancer Genome Landscapes. Science. 29 mars, vol.339, issue.6127, pp.1546-58, 2013.
1869) A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death, The Medical Journal of Australia, vol.14, pp.146-147 ,
Detection and characterization of carcinoma cells in the blood, Proc Natl Acad Sci. 14 avr, vol.95, issue.8, pp.4589-94, 1998. ,
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release, Clin Chim Acta Int J Clin Chem, vol.313, issue.1-2, pp.139-181, 2001. ,
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells, Cancer Res. 15 févr, vol.61, issue.4, pp.1659-65, 2001. ,
Free DNA in the Serum of Cancer Patients and the Effect of Therapy, 1977. ,
Liquid biopsy identifies residual breast cancer ,
,
Application of Digital PCR in Detecting Human Diseases Associated Gene Mutation, Cell Physiol Biochem, vol.43, issue.4, pp.1718-1748, 2017. ,
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med. 28 mars, vol.368, issue.13, pp.1199-209, 2013. ,
Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer, Front Med, vol.5, p.9, 2018. ,
Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies, Sci Transl Med. 19 févr, vol.6, issue.224, pp.224-248, 2014. ,
Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer, Clin Exp Med. 1 août, vol.19, issue.3, pp.271-280, 2019. ,
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial, Clin Cancer Res. 15 juin, vol.25, issue.12, pp.3581-3589, 2019. ,
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?, Cancer Treat Rev. févr, vol.73, pp.73-83, 2019. ,
Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer, Oncotarget [Internet, vol.8, issue.60, 2017. ,
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood. 2 juill, vol.126, issue.1, pp.9-16, 2015. ,
New Insights from Studies of Clonal Hematopoiesis, Clin Cancer Res. 1 oct, vol.24, pp.4633-4675, 2018. ,
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes, N Engl J Med. 25 déc, vol.371, issue.26, pp.2488-98, 2014. ,
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence, N Engl J Med. 25 déc, vol.371, issue.26, pp.2477-87, 2014. ,
Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med. déc, vol.20, issue.12, pp.1472-1480, 2014. ,
Identification of genetic variants using bar-coded multiplexed sequencing, Nat Methods. oct, vol.5, issue.10, pp.887-93, 2008. ,
Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics. 15 juill, vol.25, issue.14, pp.1754-60, 2009. ,
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res. 1 sept, vol.20, issue.9, pp.1297-303, 2010. ,
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods, Nucleic Acids Res, vol.34, issue.5, pp.1317-1342, 2006. ,
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral, J Med Genet. 9 sept, vol.43, issue.4, pp.295-305, 2005. ,
Base-Calling of Automated Sequencer Traces Using Phred. II. Error Probabilities, Genome Res. 1 mars, vol.8, issue.3, pp.186-94, 1998. ,
Base-Calling of Automated Sequencer Traces Using Phred. I. Accuracy Assessment, Genome Res. 1 mars, vol.8, issue.3, pp.175-85, 1998. ,
CADD: predicting the deleteriousness of variants throughout the human genome, Nucleic Acids Res. 8 janv, vol.47, issue.D1, pp.886-94, 2019. ,
, SILICO/IN VITRO DE 395 VARIANTS Claude Houdayer 5+# des groupes UGG + et ENIGMA # Introduction, 2017.
Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines, Am J Hum Genet. févr, vol.100, issue.2, pp.267-80, 2017. ,
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation, Hum Mutat. sept, vol.37, issue.9, pp.865-76, 2016. ,
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays, Clin Cancer Res, vol.24, issue.23, pp.5918-5942, 2018. ,
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis, Clin Cancer Res. 15 sept, vol.24, issue.18, pp.4437-4480, 2018. ,
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer, JAMA Oncol. 1 sept, vol.3, issue.9, p.1190, 2017. ,
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study), J Pathol Clin Res. 1 juill, vol.5, issue.3, pp.189-98, 2019. ,
Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer. juin, vol.11, issue.6, pp.426-463, 2011. ,
UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy, Genome Res. mars, vol.27, issue.3, pp.491-500, 2017. ,
Well-groomed participants: eyebrow plucks as surrogates for biomarker samples and a viable source of constitutional DNA, Annual Meeting of the American Society of Human Genetics, pp.18-22, 2016. ,
Somatic TP53 variants frequently confound germ-line testing results, Genet Med. août, vol.20, issue.8, pp.809-825, 2018. ,
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes, Cell Stem Cell. sept, vol.21, issue.3, pp.374-382, 2017. ,
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study, Lancet Oncol. janv, vol.18, issue.1, pp.100-111, 2017. ,
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, casecontrol study, Lancet Oncol. janv, vol.18, issue.1, pp.112-133, 2017. ,
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma, JAMA Oncol. 1 mars, vol.2, issue.3, p.370, 2016. ,
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy, Cell Stem Cell. nov, vol.23, issue.5, pp.700-713, 2018. ,
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature. févr, vol.518, issue.7540, pp.552-557, 2015. ,
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer, Nature. 16 déc, vol.493, issue.7432, pp.406-416, 2012. ,
Prediction of acute myeloid leukaemia risk in healthy individuals, Nature. juill, vol.559, issue.7714, pp.400-404, 2018. ,
Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med. 1 juill, vol.24, issue.7, pp.1015-1038, 2018. ,
Clonal Hematopoiesis and therapy related MDS/AML, Best Pract Res Clin Haematol. mars, vol.32, issue.1, pp.13-23, 2019. ,